Novo Nordisk Trails in Trade Volume as Legal Storms Offset Clinical Gains and Fund Manager Praise

On September 2, 2025, Novo Nordisk (NVO) traded with a volume of $0.65 billion, ranking 158th in market activity. The stock closed 0.14% lower, reflecting a mixed landscape of corporate developments and legal challenges.

Positive momentum emerged from clinical data showing Wegovy’s 57% reduction in cardiovascular risks compared to Eli Lilly’s tirzepatide, reinforcing its leadership in obesity treatments. The drug’s recent FDA approval for MASH and expansion into China further broadened its commercial potential. A prominent fund manager also highlighted NVO’s undervaluation, citing strong earnings and growth in diabetes and obesity markets.

However, legal pressures weighed on sentiment. Multiple class-action lawsuits were filed, alleging securities fraud related to investor losses between May and July 2025. These claims, brought by firms like Levi & Korsinsky and Bernstein Liebhard, seek damages and could impact investor confidence. Meanwhile, Rep. Marjorie Taylor Greene’s modest insider purchase and Novo Holdings’ $34 million investment in quantum computing firm Phasecraft added neutral noise to the stock’s movement.

Backtesting results indicate that NVO’s performance in the specified period aligns with the reported 0.14% decline, with no deviations in volume or price action from the provided data.